Get the Stockscreener App
13.34
0.30%
-0.00
Uniqure N V stock is traded at $13.34, with a volume of 167.30K.
It is down -0.30% in the last 24 hours and up +0.38% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$13.34
Open:
$13.37
24h Volume:
167.30K
Relative Volume:
0.08
Market Cap:
$709.49M
Revenue:
$15.84M
Net Income/Loss:
$-308.48M
P/E Ratio:
-2.0586
EPS:
-6.48
Net Cash Flow:
$-153.08M
1W Performance:
+6.31%
1M Performance:
+0.38%
6M Performance:
+134.98%
1Y Performance:
+160.27%
1-Day Range:
$13.02
$13.56
1-Week Range:
$11.45
$13.68
52-Week Range:
$3.73
$19.18
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
13.31 | 709.49M | 15.84M | -308.48M | -153.08M | -6.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.64 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
678.36 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.62 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.21 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.13 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
uniQure (NASDAQ:QURE) Stock Rating Upgraded by StockNews.com - Defense World
Oppenheimer & Co. Inc. Buys New Stake in uniQure (NASDAQ:QURE) - Defense World
FY2025 Earnings Estimate for uniQure Issued By HC Wainwright - Defense World
uniQure (NASDAQ:QURE) Earns Buy Rating from HC Wainwright - Defense World
uniQure Reports 2024 Financial Results and Progress - TipRanks
uniQure CFO Christian Klemt sells $107,407 in shares By Investing.com - Investing.com South Africa
uniQure’s chief medical officer sells shares worth $13,891 - Investing.com India
uniQure CFO Christian Klemt sells $107,407 in shares - Investing.com India
uniQure’s chief medical officer sells shares worth $13,891 By Investing.com - Investing.com South Africa
uniQure CEO Matthew Kapusta sells shares worth $291,628 By Investing.com - Investing.com South Africa
uniQure chief legal officer sells shares for $72,812 By Investing.com - Investing.com South Africa
uniQure CEO Matthew Kapusta sells shares worth $291,628 - Investing.com
uniQure chief legal officer sells shares for $72,812 - Investing.com
uniQure (NASDAQ:QURE) Stock Price Down 7.3% Following Analyst Downgrade - Defense World
Wells Fargo & Company Cuts uniQure (NASDAQ:QURE) Price Target to $30.00 - Defense World
What is William Blair’s Forecast for uniQure Q1 Earnings? - Defense World
Don't Ignore The Insider Selling In uniQure - Simply Wall St
Q1 Earnings Estimate for uniQure Issued By William Blair - Defense World
uniQure Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Insider Selling: uniQure (NASDAQ:QURE) CEO Sells 26,727 Shares of Stock - MarketBeat
uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta Sells 6,717 Shares - MarketBeat
uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 14,341 Shares - MarketBeat
uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 2,916 Shares - MarketBeat
uniQure (NASDAQ:QURE) Releases Quarterly Earnings Results, Misses Expectations By $0.90 EPS - MarketBeat
uniQure (NASDAQ:QURE) Shares Down 9.5%Should You Sell? - MarketBeat
uniQure (NASDAQ:QURE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
uniQure (NASDAQ:QURE) Given Average Rating of “Buy” by Brokerages - Defense World
Uniqure NV earnings missed by $0.82, revenue fell short of estimates - Investing.com South Africa
uniQure CEO Matthew Kapusta sells over $360,000 in stock By Investing.com - Investing.com South Africa
uniQure CEO Matthew Kapusta sells over $360,000 in stock - Investing.com India
uniQure CFO Christian Klemt sells shares worth over $186,000 By Investing.com - Investing.com South Africa
uniQure CFO Christian Klemt sells shares worth over $186,000 - Investing.com
Uniqure NV reports results for the quarter ended December 31Earnings Summary - TradingView
uniQure N.V. SEC 10-K Report - TradingView
UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
uniQure Reports 2024 Financial Results and Company Progress - TradingView
uniQure N.V. Reports Progress with AMT-130 for Huntington’s Disease and Updates on Clinical Trials Across its Gene Therapy Pipeline - Nasdaq
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress - GlobeNewswire
uniQure N.V.: A Potential Huntington's Play - Seeking Alpha
uniQure (QURE) Expected to Announce Earnings on Wednesday - Defense World
(QURE) Technical Data - Stock Traders Daily
Huntington's Disease Market Growth to Accelerate in Forecast - openPR
Pfizer nixes Roche-partnered hemophilia drug (PFE:NYSE) - Seeking Alpha
uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons - Seeking Alpha
uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66% - Yahoo Finance
24,749 Shares in uniQure (NASDAQ:QURE) Acquired by Palumbo Wealth Management LLC - MarketBeat
uniQure (NASDAQ:QURE) Stock Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
(QURE) Proactive Strategies - Stock Traders Daily
uniQure (NASDAQ:QURE) Stock Price Down 6.7%Should You Sell? - MarketBeat
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Uniqure N V Stock (QURE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Abi-Saab Walid | Chief Medical Officer |
Mar 04 '25 |
Sale |
10.29 |
1,350 |
13,891 |
151,903 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Mar 04 '25 |
Sale |
10.29 |
10,438 |
107,407 |
217,730 |
| Potts Jeannette | Chief Legal Officer |
Mar 04 '25 |
Sale |
10.29 |
7,076 |
72,812 |
119,743 |
| Kapusta Matthew C | CEO, Managing Director |
Feb 25 '25 |
Sale |
10.70 |
26,727 |
285,979 |
571,188 |
| Kapusta Matthew C | CEO, Managing Director |
Feb 27 '25 |
Sale |
11.32 |
6,717 |
76,036 |
580,795 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Feb 25 '25 |
Sale |
10.70 |
14,341 |
153,449 |
152,372 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Feb 27 '25 |
Sale |
11.32 |
2,916 |
33,009 |
155,168 |
| Kapusta Matthew C | CEO, Managing Director |
Dec 10 '24 |
Option Exercise |
14.71 |
100,000 |
1,471,000 |
697,915 |
| Kapusta Matthew C | CEO, Managing Director |
Dec 10 '24 |
Sale |
15.03 |
100,000 |
1,503,000 |
597,915 |
| Kapusta Matthew C | CEO, Managing Director |
Dec 09 '24 |
Sale |
7.63 |
3,418 |
26,079 |
597,915 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):